

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON THURSDAY, 22 MAY 2025

POLL RESULTS OF THE AGM

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 28 April 2025 (the “**Circular**”) and the notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) dated 28 April 2025. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that, all proposed resolutions as set out in the Notice were passed by way of poll at the AGM held on Thursday, 22 May 2025. All Directors attended the AGM in person or by way of video conference.

As at the date of the AGM, the total number of issued Shares was 851,263,345 Shares, and the total number of Shares entitling the holders to attend and vote for or against the resolutions at the AGM was also 851,263,345 Shares. No Shareholder entitled to attend the AGM was required to abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders is required under the Listing Rules to abstain from voting on the resolutions at the AGM. None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and approve the audited consolidated financial statements together with the directors' report and the independent auditor's report of the Company for the year ended 31 December 2024.	371,784,938 (97.47%)	9,662,424 (2.53%)
2.	(a) To re-elect Professor Zhu Quan as an executive director of the Company.	332,806,646 (87.25%)	48,640,716 (12.75%)
	(b) To re-elect Mr. Young Yuk Chuen David as an executive director of the Company.	333,319,646 (87.27%)	48,640,716 (12.73%)
	(c) To re-elect Dr. Zhang Lihua as a non-executive director of the Company.	333,392,034 (87.28%)	48,568,328 (12.72%)
	(d) To re-elect Mr. Feng Zhongshi (who has served more than 9 years) as an independent non-executive director of the Company.	376,667,719 (98.61%)	5,292,643 (1.39%)
	(e) To re-elect Professor Li Yikai as an independent non-executive director of the Company.	375,320,308 (98.26%)	6,640,054 (1.74%)
	(f) To re-elect Mr. Li Zhuoguang as an independent non-executive director of the Company.	381,336,308 (99.84%)	624,054 (0.16%)
	(g) To re-elect Mr. Duan Weiwu as an independent non-executive director of the Company.	381,336,308 (99.84%)	624,054 (0.16%)
	(h) To authorise the board of directors of the Company (the "Directors") to fix the Directors' remuneration.	336,061,246 (87.98%)	45,899,116 (12.02%)
3.	To declare and pay to the shareholders of the Company a final dividend of HKD0.3 per ordinary share of the Company for the year ended 31 December 2024.	381,960,308 (99.99999%)	54 (0.00001%)
4.	To re-appoint KPMG as auditors of the Company and to authorise the board of Directors to fix their remuneration.	373,451,958 (97.77%)	8,508,404 (2.23%)
5.	To grant a general and unconditional mandate to the Directors to allot, issue and deal with the additional ordinary shares of the Company with the total number of shares not exceeding 20% of the total number of the issued shares of the Company.	241,703,617 (63.28%)	140,256,745 (36.72%)

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
6.	To grant a general and unconditional mandate to the Directors to repurchase shares of the Company with the total number of shares not exceeding 10% of the total number of the issued shares of the Company.	381,479,308 (99.87%)	481,054 (0.13%)
7.	To extend the general and unconditional mandate granted to the Directors to issue, allot and deal with additional shares of the Company under resolution numbered 5 to include the number of shares of the Company repurchased pursuant to the general and unconditional mandate to repurchase shares under resolution numbered 6.	245,392,632 (64.25%)	136,567,730 (35.75%)

* *The full text of resolutions no. 5 to no. 7 are set out in the Notice.*

As more than 50% of the votes were cast in favour of each of the resolutions (resolutions no. 1 to no. 7), all such resolutions were duly passed by the Shareholders by way of poll.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

By Order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 22 May 2025

As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.